CD47 target: from theory to reality
Journal: Biomedical Research and Therapy (Vol.1, No. 2)Publication Date: 2014-10-04
Authors : John Wu;
Page : 35-36
Keywords : CD47; cancer targeting therapy; Immunotherapy; Gene therapy;
Abstract
Irving Weissman at the Stanford University School of Medicine in Palo Alto, California found that leukemia cells produced higher levels of CD47. This high expression help tumor cells to escape from the immune system. To date, the CD47 receptor becomes the interesting target in cancer treatment. Some recent studies from in vitro to pre-clinical trials showed that blocking CD47 by anti-CD47 or morpholino efficiently tumor cells or tumor growth. From these results, some clinical trials were suggested to test the safety and efficacy of anti-CD47 therapy. There is at least a clinical trial using anti-CD47 therapy registered in clinicaltrial.gov. Some other clinical trials will be performed at Stanford in the mid-2014 as well as in the United Kingdom.
Other Latest Articles
- Euler and applications of quantum mechanics. Paradox IH. Part
- Biological therapy: a new age of cancer treatment
- Platelet-rich plasma in regenerative medicine
- Inventions in the nanotechnological area provide improved performance characteristics of different sealing polymer materials used in construction
- The latest foreign achievements in the area of nanotechnologies and nanomaterials. Part 1
Last modified: 2014-10-04 22:12:36